Quick answer
Rosacea affects about 5.5% of the world's population, and its defining feature — persistent facial redness — comes from permanently dilated vessels in the skin. Lasers and topical vasoconstrictors help temporarily; nothing reverses the vessel state. Li Ji and Deng Zhili at Xiangya Hospital, with Sun Jinpeng and Guo Lulu at Shandong University, found the molecular switch: the metabolite alpha-ketoglutarate activates a receptor called OXGR1 on vascular smooth muscle, which constricts the vessel. They then used AI-assisted design to build an agonist that works the same way, published in Cell on 5 March 2026 [1][2][5].
Key takeaways
- Published in Cell on 5 March 2026; Xiangya Hospital is first and first corresponding institution [1][2].
- Serum alpha-ketoglutarate is elevated in rosacea patients and correlates with erythema severity [4].
- Alpha-ketoglutarate binds and activates OXGR1, a Gq-coupled receptor on vascular smooth muscle [5].
- Signalling proceeds through MLCK-dependent phosphorylation of myosin light chain 9, causing contraction [3].
- An AI-designed selective agonist, A-1, improved rosacea-like erythema in mice at low dose [5].
The logic of the finding
The team started from serum metabolomics rather than from a hypothesis about blood vessels. Comparing rosacea patients with healthy controls, they found alpha-ketoglutarate — a Krebs cycle intermediate — raised, and the higher the level, the worse the redness. That correlation alone could be a consequence of inflammation rather than a cause, which is why the receptor work matters: the metabolite has a specific target on the cell type that controls vessel calibre [2][4].
If alpha-ketoglutarate rises as a compensatory attempt to constrict over-dilated vessels, then supplying more of it — or a better agonist — should help. That is the interpretation the authors favour: the metabolite elevation is a self-protective signal, and the drug amplifies it [5].
From mechanism to molecule
Alpha-ketoglutarate itself is a poor drug: it is ubiquitous, rapidly metabolised, and activates many pathways. The team therefore solved the structure of OXGR1 with its natural ligands and used AI-assisted methods to design a molecule with high activity and selectivity for this receptor, then confirmed that low doses reduced erythema in a mouse model [3][5].
The evidence is mechanistic and preclinical. No human trial of A-1 is reported, and mouse rosacea-like models do not reproduce the chronic, remitting course of the human disease. Long-term vasoconstriction in facial skin raises its own questions — whether tolerance develops, and whether reducing blood flow has consequences for skin health. The pathway is nonetheless a genuine advance: it explains a clinical sign that had no molecular explanation [1][3].
The condition in context: rosacea
Rosacea is chronic, relapsing and visible, and treatment options for the redness itself are limited.
| Region | What the data shows | Source |
|---|---|---|
| Prevalence | About 5.5% of the global population is affected [1][2]. | Xiangya Hospital [1][2] |
| Subtypes | Erythematotelangiectatic, papulopustular, phymatous and ocular forms, often overlapping [6]. | Tencent Medical Encyclopedia [6] |
| Treatment gap | Options for persistent erythema are limited, of modest benefit and with side effects [1]. | Xiangya Hospital [1] |
Because the redness is the most visible and least treatable component, a vasoactive mechanism addresses the main unmet need [3].
Why it matters
| Potential | What the report suggests | Source |
|---|---|---|
| Explanation | First molecular account of persistent rosacea erythema [2][5]. | [2][5] |
| New target | OXGR1 is a tractable G-protein-coupled receptor [4]. | [4] |
| Caution | Preclinical only; no human data [3]. | [3] |
Availability and limits
- This is an editorial summary of a research paper, not a treatment recommendation [1][2].
- A-1 has not been tested in humans [3].
- Mouse models do not capture chronic human rosacea [5].
- Topical delivery to facial skin and long-term vascular effects are unresolved [1].
- Patients should not self-treat with alpha-ketoglutarate supplements on this basis [6].
What to ask before booking
| Question | Why it matters |
|---|---|
| Which rosacea subtype do I have? | Papulopustular and erythematotelangiectatic disease need different treatments [6]. |
| Are any trials of OXGR1 agonists open? | None is reported to date [3]. |
| Which department handles foreign patients, and in what language? | Xiangya is a working hospital we do not book; confirm international-department coordination and language support. |
| What are the current options for my redness? | Lasers, topicals and trigger avoidance remain standard [1]. |
Questions patients ask
What did the study find?
Alpha-ketoglutarate is elevated in rosacea patients and activates OXGR1 on vascular smooth muscle, causing vasoconstriction through Gq and MYL9 phosphorylation; the team designed an OXGR1 agonist, A-1, that reduced rosacea-like erythema in mice [1][4][5].
Where was it published?
Cell, online 5 March 2026, with Xiangya Hospital as first and first corresponding institution [1][2].
Who collaborated?
Li Ji and Deng Zhili at Xiangya Hospital with Sun Jinpeng and Guo Lulu at Shandong University [1][3].
Is a drug available?
No — A-1 is preclinical; no human trial is reported [3].
Is this relevant to international patients?
It is useful context for China's dermatology research. Xiangya is a working hospital we do not book — contact its international department directly [1].